Dun & Bradstreet Logo

Jason Cother

Lost patent protection impacting Eli Lilly

by Jason Cother | Dun & Bradstreet Editor

April 15, 2015 | Comments Off on Lost patent protection impacting Eli Lilly

In an update last week, Dun & Bradstreet editor Diane Ramirez discussed Eli Lilly’s uneven financial performance over the past several years as many of its significant drugs lose patent protection. Revenue was down 15% in 2014 (to $19.6 billion) on lower sales of antidepressant Cymbalta (which lost patent protection in December 2013) and osteoporosis treatment Evista (which lost patent protection in March 2014), among other factors. Hoping for a new blockbuster, the pharmaceutical giant launched three new medicines in 2014 and has some 60 candidates in clinical development stages. Follow Diane on Twitter.